Single-arm phase II study of low-dose paclitaxel and pembrolizumab in platinum-refractory metastatic urothelial carcinoma (UC).

被引：2
|
作者：
Bitting, Rhonda L. [1 ]
Vile, Donald Charles [2 ]
Tooze, Janet A. [3 ]
Thomas, Christopher Y. [1 ]
Neve, Morgan [1 ]
Kooshki, Mitra [1 ]
Brown, Jessica [4 ]
Dubey, Purnima [4 ]
Triozzi, Pierre [1 ]
Goodman, Michael Moses [1 ]
机构：
[1] Wake Forest Baptist Hlth, Ctr Comprehens Canc, Winston Salem, NC USA
[2] Wake Forest Baptist Hlth, Winston Salem, NC USA
[3] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA
[4] Ohio State Univ, Pelotonia Inst Immunooncol, James Comprehens Canc Ctr, Columbus, OH 43210 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2021年 / 39卷 / 06期
关键词：
D O I：
10.1200/JCO.2021.39.6_suppl.433
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
433
引用
收藏
页数：3
相关论文
共 50 条
  • [1] Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
    Bitting, Rhonda L.
    Tooze, Janet A.
    Goodman, Michael
    Vile, Donald C.
    Brown, Jessica M.
    Thomas, Christopher Y.
    Neve, Morgan
    Kooshki, Mitra
    Addo, Safoa
    Triozzi, Pierre L.
    Dubey, Purnima
    CANCER RESEARCH COMMUNICATIONS, 2024, 4 (02): : 530 - 539
  • [2] Results of a phase II study of single-agent nab-paclitaxel in platinum-refractory second-line metastatic urothelial carcinoma (UC)
    Sridhar, S. S.
    Canil, C. M.
    Mukherjee, S. D.
    Winquist, E.
    Elser, C.
    Eisen, A.
    Reaume, M. N.
    Zhang, L.
    Ko, Y.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (07)
  • [3] Phase 2 study of pembrolizumab alone or combined with acalabrutinib in platinum-refractory metastatic urothelial carcinoma (mUC)
    Zhang, T.
    Harrison, M.
    O'Donnell, P.
    Alva, A.
    Hahn, N.
    Appleman, L. J.
    Cetnar, J.
    Burke, J.
    Fleming, M.
    Milowsky, M.
    Mortazavi, A.
    Shore, N.
    Schmidt, E. V.
    Kresja, C.
    Chen, T.
    Bitman, B.
    Izumi, R.
    Hamdy, A.
    George, D. J.
    ANNALS OF ONCOLOGY, 2017, 28
  • [4] Afatinib activity in platinum-refractory metastatic urothelial carcinoma (UC) patients with ErbB alterations: Results of a phase II trial.
    Choudhury, Noura
    Campanile, Alexa
    Antic, Tatjana
    Wade, James Lloyd
    Stadler, Walter Michael
    Nakamura, Yusuke
    O'Donnell, Peter H.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (02)
  • [5] Pembrolizumab and nanoparticle albumin bound paclitaxel (nabpaclitaxel) for metastatic urothelial carcinoma (UC) after chemotherapy failure: the open-label, single-arm, phase 2 PEANUT study
    Necchi, A.
    Mariani, L.
    Anichini, A.
    Giannatempo, P.
    Raggi, D.
    Calareso, G.
    Salvioni, R.
    ANNALS OF ONCOLOGY, 2017, 28
  • [6] Pembrolizumab and nab-paclitaxel as salvage therapy for platinum-treated, locally advanced or metastatic urothelial carcinoma: interim results of the open-label, single-arm, phase II PEANUT study
    Giannatempo, P.
    Raggi, D.
    Marandino, L.
    Bandini, M.
    Fare, E.
    Calareso, G.
    Colecchia, M.
    Gallina, A.
    Ross, J. S.
    Alessi, A.
    Briganti, A.
    Montorsi, F.
    Madison, R.
    Necchi, A.
    ANNALS OF ONCOLOGY, 2020, 31 (12) : 1764 - 1772
  • [7] Camrelizumab plus nab-paclitaxel in platinum-resistant patients with unresectable locally advanced or metastatic urothelial carcinoma: A multicentre, single-arm, phase II study
    Li, H.
    Chen, M.
    Xue, C.
    Li, L.
    Hu, A.
    Yang, W.
    Zheng, Z.
    Ni, M.
    Zhang, L.
    Zeng, Y.
    Peng, J.
    Yao, K.
    Zhou, F.
    Liu, Z.
    An, X.
    Shi, Y.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1335 - S1335
  • [8] Phase II study of high-dose paclitaxel in platinum-refractory epithelial ovarian cancer
    Wilailak, S
    Tresukosol, D
    Linasmita, V
    Termrungruanglert, W
    EUROPEAN JOURNAL OF GYNAECOLOGICAL ONCOLOGY, 2000, 21 (06) : 610 - 612
  • [9] Anlotinib in patients with recurrent platinum-resistant or platinum-refractory ovarian carcinoma: A prospective, single-center, single-arm, phase II clinical trial
    Wang, Huaying
    Shan, Boer
    Tian, Wenjuan
    GYNECOLOGIC ONCOLOGY, 2022, 166 : S23 - S23
  • [10] INTERIM RESULTS OF PEANUT: AN OPEN-LABEL, SINGLE-ARM, PHASE 2 STUDY EVALUATING PEMBROLIZUMAB PLUS NANOPARTICLE ALBUMIN-BOUND PACLITAXEL (NAB-PACLITAXEL) AS SALVAGE THERAPY FOR METASTATIC UROTHELIAL CARCINOMA (UC)
    Necchi, Andrea
    Raggi, Daniele
    Bandini, Marco
    Fare, Elena
    Giannatempo, Patrizia
    Colecchia, Maurizio
    Pederzoli, Filippo
    Gallina, Andrea
    Marandino, Laura
    Calareso, Giuseppina
    Madison, Russell
    Briganti, Alberto
    Ross, Jeffrey
    Montorsi, Francesco
    JOURNAL OF UROLOGY, 2020, 203 : E1083 - E1083
12345